Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Published on January 16, 2013 at 4:26 AM · No Comments

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder. It is a randomized, double-blind, placebo-controlled, four-arm, global multi-center Phase 2 study to assess the efficacy, safety and tolerability of RP5063 in male and female patients with schizophrenia. A total of 234 schizophrenia patients were enrolled in this phase 2 study from USA, Asia and Europe. Top-line results from this trial are expected to be announced by the end of February 2013 (For more details please visit: and identifier: NCT01490086).

"Schizophrenia is a devastating mental disease with much unmet treatment need," said Dr. Laxminarayan Bhat, President and Chief Executive Officer of Reviva Pharmaceuticals. "We are optimistic that the results of this trial will establish clinical proof of concept on safety and efficacy to reveal RP5063 as a promising therapeutic option for treating schizophrenia and schizoaffective disorder."


Reviva Pharmaceuticals, Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Biological Psychiatry special issue highlights role of dopamine signaling in schizophrenia